Matej Krivulka, Elise J Heesbeen, Lukas Vaišvilas, Emma Marshall, Anne Metje van Genderen, Rosalinde Masereeuw, Paula Perez Pardo, Quentin Faucher
{"title":"Afferent Renal Nerves Extend the Landscape of the Kidney-Brain Axis in Health and Disease.","authors":"Matej Krivulka, Elise J Heesbeen, Lukas Vaišvilas, Emma Marshall, Anne Metje van Genderen, Rosalinde Masereeuw, Paula Perez Pardo, Quentin Faucher","doi":"10.14336/AD.2026.0632","DOIUrl":"https://doi.org/10.14336/AD.2026.0632","url":null,"abstract":"<p><p>Emerging evidence suggests a pathophysiological crosstalk between kidney disease and several brain disorders, highlighting the importance of the kidney-brain axis and the potential consequences of its impairment. The kidney-brain axis is a dynamic, intricate bidirectional network essential for maintaining body homeostasis. This crosstalk is influenced by systemic factors such as accumulating endogenous waste products (uremic toxins) and chronic inflammation resulting from impaired kidney function. Beyond waste excretion, the kidneys function as interoceptive organs, detecting mechanical, chemical, and nociceptive stimuli through a dense network of afferent renal nerves. Signals are transmitted to the central nervous system to modulate sympathetic outflow, fluid and electrolyte balance, and blood pressure. Despite a general understanding of the renal innervation anatomy and interoceptive function via the inhibitory renorenal reflex, the specific intricacies of afferent renal nerves are still limited. Significant knowledge gaps remain regarding the phenotype of renal mechano- and chemoreceptors, the precise molecular transducers involved, and their maladaptive remodelling during kidney disease and potential involvement in brain disorders. This review defines the kidney-brain axis as an integrated neurohumoral communication network through which the kidney and brain coordinate and adapt to physiological stresses. We describe the anatomical distribution of efferent and afferent nerves within the nephrons, map the kidney-to-brain signal transmission, describe known molecular pathways, and examine the implications of altered renal afferent signalling in kidney-related comorbidities, including neurological disorders. We shed light on the therapeutic potential of targeting renal sensory nerves to mitigate renal and neurological decline in the context of an ageing global population.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiayi Xu, Zhiwen Cao, Yansong Liu, Aibo Gao, Yanyan Kong
{"title":"Fecal Microbiota Transplantation in Alzheimer's Disease: A Scoping Review of Human, Registry, and Preclinical Evidence.","authors":"Jiayi Xu, Zhiwen Cao, Yansong Liu, Aibo Gao, Yanyan Kong","doi":"10.14336/AD.2026.0883","DOIUrl":"https://doi.org/10.14336/AD.2026.0883","url":null,"abstract":"<p><p>Fecal microbiota transplantation (FMT) is being explored as a microbiota-directed intervention for Alzheimer's disease (AD), with evidence drawn mainly from preclinical studies. This scoping review mapped published human reports, registered trials and animal microbiota-transfer studies to inform FMT research in AD. Five human reports, eight unique registered trials and 34 animal studies were included. Four human reports concerned FMT administered for Clostridioides difficile infection (CDI). The remaining report was an uncontrolled five-patient pilot comprising two patients with AD, two with mild cognitive impairment (MCI) and one with frontotemporal dementia (FTD). It described maintained cognition in AD and FTD and improvement or maintenance in MCI. The published human studies were nonrandomized. Among the eight registered trials, two required AD biomarker confirmation and two specified donor-referenced engraftment outcomes. Among 30 animal studies assessing cognition, 24 reported positive findings and six mixed findings. Restriction to genetic/transgenic AD models reduced the positive proportion from 24/30 (80.0%) to 17/23 (73.9%). Cognition-specific randomization and blinding were reported in 16/30 (53.3%) and 4/30 (13.3%) studies, respectively. The evidence supports early-phase investigation, with attention to donor and product characterization, appropriate comparators, and separate measurement of engraftment, microbial function, systemic responses and AD outcomes. Safety data remain insufficient for patients with AD, particularly outside the CDI setting. FMT should remain investigational for AD.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tissue- and Organ-Related Molecular Aging Clocks: Measurement, Interpretation, and Translational Validation.","authors":"Ting Wang, Shiqing Xie, Lihua Yu, Ting Xu","doi":"10.14336/AD.2026.1010","DOIUrl":"https://doi.org/10.14336/AD.2026.1010","url":null,"abstract":"<p><p>Biological age measures are increasingly derived from target tissues, proximal fluids, and circulating signals, but whether they represent aging of a specific organ remains uncertain. Differences in sample source, biological resolution, and validation make predicted ages and age gaps from these pathways non-interchangeable. This critical narrative review compares representative molecular clocks of the central nervous system and peripheral organs and introduces the source, resolution, and validation framework, abbreviated as S-R-V, to assess the organ attribution and translational claims supported by each model. Across organs, molecular age measures were linked to different aspects of organ state and biological context. Chronological age prediction was more consistently demonstrated than alignment with organ pathology or function. Age gaps may reflect varying contributions from organ-related signals, cellular composition, systemic influences, disease-related remodeling, and technical or modeling effects. Correlations among organ age gaps represented dependence among model outputs and did not establish communication, temporal ordering, or causality between organs. Evidence was concentrated in model development, external replication, and cross-sectional disease association, while prospective prediction, longitudinal responsiveness, and clinical utility were less developed. Future studies should pair target tissue, proximal fluid, and circulating measures with organ pathology or function in the same participants and use repeated measurements to determine whether accessible measures track within-person change. By matching measurement context to validation evidence, S-R-V can help define when organ age measures support risk stratification, longitudinal monitoring, or intervention evaluation.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ji-Sun Kim, Jin-A Kim, Young Hun Jung, Jung-Won Choi, Sung Won Shin, Byeongkyu Kang, Byung Soh Min, Hunsang Lee, Seok Chung, Sung-Joon Lee
{"title":"Olfactory Receptor 51E2 Activation by β-Ionone Induces a Senescence-Like Phenotype and Increases Susceptibility to Senolytic Treatment in Colorectal Cancer.","authors":"Ji-Sun Kim, Jin-A Kim, Young Hun Jung, Jung-Won Choi, Sung Won Shin, Byeongkyu Kang, Byung Soh Min, Hunsang Lee, Seok Chung, Sung-Joon Lee","doi":"10.14336/AD.2026.1095","DOIUrl":"https://doi.org/10.14336/AD.2026.1095","url":null,"abstract":"<p><p>Olfactory receptor 51E2 (OR51E2) is markedly downregulated in colorectal cancer (CRC), yet its functional activation by its natural agonist, β-ionone, suppresses CRC cell growth. In this study, we investigated the tumor-suppressive effects of β-ionone-mediated OR51E2 activation using human CRC cell lines (SW480, SW620, and RKO) and patient-derived organoids (PDOs). We demonstrate that β-ionone treatment stimulates intracellular calcium levels in an OR51E2-dependent manner, upregulating MAPK-directed phosphatases (DUSP1/2/4 and PPP1CA). This calcium-dependent phosphatase activation suppresses the MEK1/2-ERK1/2 signaling axis, leading to G0/G1 cell cycle arrest via the downregulation of CDK2/4/6 and cyclin A/D1. Concurrently, OR51E2 activation induces a senescence-like phenotype, evidenced by increased senescence-associated β-galactosidase activity, chromatin remodeling (reduced LAMIN B1 and increased H3K27me3), and upregulated p16/p21 expression alongside senescence-associated secretory phenotype (SASP) factors. These phenotypic and mechanistic findings were fully recapitulated in CRC-PDOs representing distinct clinical subtypes. Crucially, the residual senescence-like cell population showed increased susceptibility to dasatinib plus quercetin (DQ), which reduced senescence-associated markers and increased apoptosis. Collectively, this study demonstrates that OR51E2 activation coordinates a heterogeneous cell-fate decision encompassing both apoptosis and a senescence-like phenotype. Our findings highlight ectopic olfactory receptor signaling as an underexplored mechanism of tumor suppression and provide in vitro evidence for a sequential approach in CRC in which β-ionone-mediated OR51E2 activation induces a senescence-like state followed by senolytic treatment.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jackie M Poos, Esther van den Berg, Liset de Boer, Sabrina Meertens-Gunput, Elise G P Dopper, Harro Seelaar, Lize C Jiskoot
{"title":"Corrigendum to \"Neuropsychological Profiles in Genetic Frontotemporal Dementia: A Meta-Analysis and Systematic Review\".","authors":"Jackie M Poos, Esther van den Berg, Liset de Boer, Sabrina Meertens-Gunput, Elise G P Dopper, Harro Seelaar, Lize C Jiskoot","doi":"10.14336/AD.2026.0920-C","DOIUrl":"https://doi.org/10.14336/AD.2026.0920-C","url":null,"abstract":"","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"F-box Protein-Mediated Regulation of Cell Fate in Skeletal Homeostasis and Orthopedic Degenerative Diseases: Integrated Mechanisms and Targeted Translation.","authors":"Huijun Zhang, Youwen Liu, Zhaojie Yang, Ruoping Yanzhang, Yin Yu, Shiren Luo, Qi Gao, Jiayi Guo, Yiting Lei, Chen Yue","doi":"10.14336/AD.2026.1155","DOIUrl":"https://doi.org/10.14336/AD.2026.1155","url":null,"abstract":"<p><p>Skeletal disorders are a leading cause of disability and socioeconomic burden globally. Despite advances in molecular research, the field remains limited owing to a fragmented mechanistic understanding and a lack of unified regulatory and therapeutic frameworks. F-box proteins (FBPs), as substrate recognition components of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complexes, control ubiquitin-dependent protein degradation and are increasingly recognized as key upstream regulators of skeletal homeostasis. Emerging evidence indicates that FBPs sustain physiological bone and cartilage integrity as well as drive disease progression by orchestrating cell fate. This review summarizes the molecular basis of FBP-mediated ubiquitination and integrates current evidence into a unified framework wherein FBPs coordinate skeletal cell fate through four interconnected regulatory axes: metabolic reprogramming, immuno-inflammatory regulation, epigenetic reprogramming, and bone microenvironment remodeling. Therapeutic opportunities, translational challenges, and future research priorities are also discussed. By integrating current evidence, this review establishes a conceptual framework for identifying shared molecular vulnerabilities across refractory orthopedic diseases and advancing precision ubiquitin-based therapeutics targeting skeletal cell fate.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ceruloplasmin in Disorders of the Nervous System.","authors":"Masoumeh Pourhadi, Peter A LeWitt, Sokol V Todi","doi":"10.14336/AD.2026.0988","DOIUrl":"https://doi.org/10.14336/AD.2026.0988","url":null,"abstract":"<p><p>Ceruloplasmin (Cp) is a multicopper ferroxidase that links copper handling, iron export, and redox homeostasis. Within the nervous system, these functions are critical because disruption of iron and copper balance can amplify oxidative stress, neuroinflammation, and neuronal vulnerability. Although Cp has long been studied as a circulating biomarker, most reports characterize it only by protein concentration, leaving its enzymatic and structural status comparatively unexplored. Here, we synthesize human literature on Cp across major neurological disorders, with attention to studies that assess Cp's ferroxidase activity, oxidation, fragmentation, and copper-binding state alongside its circulating levels. The evidence is by far most extensive in Alzheimer's and Parkinson's diseases, which together account for the majority of the reviewed literature: reduced ferroxidase activity, increased Cp oxidation, and altered non-Cp-bound copper are repeatedly linked to disease severity, regional iron accumulation, and biomarker-defined patient subgroups; in several studies, these alterations were independent of total Cp concentration. A smaller but growing body of evidence in amyotrophic lateral sclerosis, multiple sclerosis, essential tremor, and the cerebellar ataxias points to a related pattern of Cp-linked iron mishandling contributing to neuronal vulnerability. Preliminary findings from a few small studies in schizophrenia and a single study in obsessive-compulsive disorder further suggest that circulating Cp levels track systemic inflammatory and oxidative states in these conditions. From these investigations, a picture emerges where Cp's functional and structural integrity, rather than its abundance alone, is the more informative correlate of disease-relevant metal dyshomeostasis, most clearly demonstrated in Alzheimer's and Parkinson's diseases. Based on this body of work, we propose that future studies adopt combined assessments of Cp quantity and function to clarify disease-specific Cp signatures and to evaluate whether correcting Cp activity or copper/iron imbalance can improve outcomes.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PARP-CD38-Driven NAD<sup>+</sup> Loss in Immune Aging: An Emerging Mechanistic Framework.","authors":"Umar Ali, Ruirui Tan, Sen Ding, Shanming Ji","doi":"10.14336/AD.2026.0890","DOIUrl":"https://doi.org/10.14336/AD.2026.0890","url":null,"abstract":"<p><p>Immune aging is characterized by inflammaging, progressive immune decline, and compromised tissue surveillance. Although researchers have recognized an association between PARP hyperactivation and immune aging (emerging and context-dependent), a unifying framework for how PARP members beyond PARP1 orchestrate immune dysfunction via NAD<sup>+</sup> metabolism is lacking. We propose a context-dependent PARP-CD38-NAD<sup>+</sup>-inflammaging hierarchy. PARP1 is the most abundant nuclear PARP, responsible for 85-90% of nuclear PARP activity and dominant NAD<sup>+</sup> consumption under acute DNA damage; CD38, the principal NAD<sup>+</sup> glycohydrolase, is upregulated in inflamed aged tissues; NAD<sup>+</sup> is compartmentalized (cytosolic, mitochondrial) with distinct regulators (NAMPT, NMNAT1/2/3, SLC25A51). Recent human data challenge the universal NAD<sup>+</sup> decline hypothesis, showing that an 85% muscle NAD<sup>+</sup> reduction does not impair function, and whole-blood NAD<sup>+</sup> is age-invariant. Thus, NAD<sup>+</sup> decline is tissue- and compartment-specific; blood NAD<sup>+</sup> is not a reliable biomarker. Beyond PARP1, PARP2 (cardiomyocyte aging in mouse), PARP3 (intestinal aging), PARP16 (vascular aging), and PARP9/14 (Alzheimer's models) act as tissue-specific regulators, but their roles in human immune aging remain unquantified. PARP inhibitors and NAD<sup>+</sup> precursors show promise but face risks: genomic instability, hematopoietic toxicity, senescence promotion, and inconsistent efficacy. Unresolved questions, whether PBMC PARP activity predicts immune aging, sex differences, and whether partial inhibition reduces NAD<sup>+</sup> consumption without compromising DNA repair. By rethinking PARPs as context-dependent integrators, we provide a framework for immunogerontology.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exercise, Dynamic Functional Connectivity, and Sex in Alzheimer's Disease: A Hypothesis-Generating Framework for the Sex-Dependent Dynamic Reconstitution Model.","authors":"Zehui Gong, Zhaobing Xiang, Liang Xiang, Jianrong Yuan","doi":"10.14336/AD.2026.1096","DOIUrl":"https://doi.org/10.14336/AD.2026.1096","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is increasingly viewed as a disorder of large-scale brain network dynamics. Whether exercise-related changes in dynamic functional connectivity (dFC) reflect neural reorganization, vascular effects, or both remains uncertain, and most studies have not tested sex as a moderator. We propose the Sex-Dependent Dynamic Reconstitution Model (SDDRM) as a hypothesis-generating framework. Exercise may influence temporal flexibility (a dynamic connectivity metric) through partially sex-dependent pathways. In females, estrogen-BDNF signaling may potentiate medial temporal lobe (MTL) flexibility gains from aerobic exercise, but this possibility is constrained by menopausal status, age, menopausal hormone therapy (MHT; also known as hormone replacement therapy, HRT) exposure, and limited direct evidence. In males, structured exercise may preferentially influence default mode-frontoparietal coupling through IGF-1-related mechanisms. Evidence for these pathways is predominantly indirect and preclinical, and male and female pathways may overlap substantially. We outline four candidate, sex-stratified predictions: (1) sex may moderate exercise-related MTL flexibility changes, with menopausal status as an exploratory moderator; (2) dynamic flexibility changes may partially mediate cognitive improvement, with indirect pathway magnitudes compared using moderated mediation; (3) exercise cessation may produce different flexibility decay trajectories by sex; and (4) exercise modality may interact with sex. We emphasize dFC methodological caveats-including scan duration, motion, test-retest reliability, and neurovascular coupling-and distinguish biomarker-confirmed AD from MCI and cognitively unimpaired populations. This framework is intended to guide hypothesis-driven, sex-stratified research, not clinical exercise prescriptions.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jaemin Shin, Yu Jeong Park, Seungyun Lee, Jimin Kang, Seongin Lee, Eun Seong Lee, Hye Na Jung, Inseon Ryoo, Su Jin Chung, Jae Seon Eo, Sang-Il Suh, Kyungmi Oh, Seong-Beom Koh, Sung Hoon Kang
{"title":"Baseline Physical Frailty Predicts Clinical Outcomes During Lecanemab Therapy in Early Alzheimer's Disease: A Prospective Real-World Cohort Study.","authors":"Jaemin Shin, Yu Jeong Park, Seungyun Lee, Jimin Kang, Seongin Lee, Eun Seong Lee, Hye Na Jung, Inseon Ryoo, Su Jin Chung, Jae Seon Eo, Sang-Il Suh, Kyungmi Oh, Seong-Beom Koh, Sung Hoon Kang","doi":"10.14336/AD.2026.0978","DOIUrl":"https://doi.org/10.14336/AD.2026.0978","url":null,"abstract":"<p><strong>Background: </strong>Physical frailty and sarcopenia are recognized as determinants of Alzheimer's disease (AD) progression, but their implications during anti-amyloid therapy remain unclear. We investigated their associations with longitudinal cognitive outcomes, treatment safety, tolerability, and plasma p-tau217 trajectories in patients with early AD receiving lecanemab.</p><p><strong>Methods: </strong>This prospective cohort included 187 patients with amyloid-positive early AD who initiated lecanemab at a tertiary memory clinic. Physical frailty was defined using the Short Physical Performance Battery (SPPB), and sarcopenia according to the 2019 Asian Working Group for Sarcopenia criteria. Logistic regression was used for infusion-related reactions (IRRs) and treatment discontinuation, whereas amyloid-related imaging abnormalities (ARIA) outcomes were evaluated using Firth penalized logistic regression because of the limited number of events. Longitudinal cognitive outcomes and plasma p-tau217 trajectories were analyzed using linear mixed-effects models.</p><p><strong>Results: </strong>SPPB-defined physical frailty and sarcopenia were associated with faster CDR-SB worsening (β = 1.52 and 1.40 points/year, respectively; both nominal p<0.001; both q<0.001). A greater decline in SNSB-D was observed in participants with SPPB-defined physical frailty (β=-11.36 points/year; 95% CI, -22.38 to -0.34; nominal p=0.044), although this association did not remain statistically significant after FDR correction (q=0.065). Neither exposure was associated with MMSE change. SPPB-defined physical frailty was associated with a higher risk of IRRs (adjusted odds ratio, 4.75; 95% confidence interval, 2.03-11.66; p<0.001), but was not associated with ARIA or treatment discontinuation. No differential plasma p-tau217 trajectories were detected according to baseline SPPB-defined physical frailty or sarcopenia status.</p><p><strong>Conclusions: </strong>Baseline SPPB-defined physical frailty was associated with longitudinal clinical progression and IRRs during lecanemab treatment. These findings suggest that SPPB-defined physical frailty may represent a candidate prognostic marker of clinical outcomes during lecanemab therapy and warrant further validation in larger cohorts.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":9.6,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}